Login / Signup

Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial.

Luis Ricardo Balleza AlejandriFernando Grover PáezErick González CamposCarlos G Ramos BecerraErnesto Germán Cardona MuñózSara Pascoe GonzálezMaría Guadalupe Ramos ZavalaAfrica Samantha Reynoso RoaDaniel O Suarez RicoAlberto Beltrán RamírezJesús Jonathan García GalindoDavid Cardona MüllerClaudia Yanette Galán Ruíz
Published in: Journal of cardiovascular development and disease (2024)
After the treatment period, the empagliflozin and dapagliflozin groups achieved similar FMD, suggesting a class effect.
Keyphrases
  • clinical trial
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • open label
  • phase iii